Maplight Therapeutics (NASDAQ:MPLT) Director George Pavlov Purchases 9,920 Shares of Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director George Pavlov bought 9,920 shares of the company’s stock in a transaction on Friday, February 20th. The shares were bought at an average cost of $17.86 per share, for a total transaction of $177,171.20. Following the transaction, the director owned 25,000 shares in the company, valued at $446,500. The trade was a 65.78% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link.

George Pavlov also recently made the following trade(s):

• On Thursday, February 19th, George Pavlov purchased 4,422 shares of Maplight Therapeutics stock. The shares were purchased at an average price of $17.57 per share, for a total transaction of $77,694.54.
• On Wednesday, February 18th, George Pavlov acquired 10,658 shares of Maplight Therapeutics stock. The stock was purchased at an average price of $17.48 per share, with a total value of $186,301.84.

Maplight Therapeutics Trading Down 0.2%

NASDAQ MPLT traded down $0.04 during trading hours on Friday, reaching $17.88. The stock had a trading volume of 120,504 shares, compared to its average volume of 184,868. Maplight Therapeutics, Inc. has a 52-week low of $12.24 and a 52-week high of $21.55. The company’s fifty day moving average is $17.93. The stock has a market cap of $811.27 million and a PE ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. acquired a new stake in Maplight Therapeutics in the 4th quarter valued at $49,168,000. Invesco Ltd. purchased a new stake in Maplight Therapeutics during the 4th quarter worth $228,000. Vestal Point Capital LP acquired a new position in shares of Maplight Therapeutics in the fourth quarter worth about $6,763,000. Tudor Investment Corp ET AL purchased a new position in shares of Maplight Therapeutics during the 4th quarter valued at approximately $840,000. Finally, Orbimed Advisors LLC bought a new position in Maplight Therapeutics during the 4th quarter valued at $952,000.

Analysts Set New Price Targets

A number of research analysts recently commented on MPLT shares. Jefferies Financial Group initiated coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $32.00 price objective on the stock. Weiss Ratings began coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Leerink Partners assumed coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued an “outperform” rating and a $30.00 target price for the company. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. Finally, Stifel Nicolaus began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $28.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.00.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.